Educator Therapy is not yet commercially available. We are currently undergoing the FDA approval process and aim to be commercially approved within the next two years (2027). You can receive Educator therapy if you meet the criteria of FDA-approved clinical trials. Alternatively, we can offer the Educator therapy via the Right-to-Try (RTT) program.
We are accepting applicants for our Type 1 Diabetes clinical trial in New Jersey. The Type 1 Diabetes trial will require 5 follow-ups after the treatment with Stem Cell Educator therapy. Please email connect@thronebio.com and our clinical team will determine your eligibility.
Educator Therapy is treating Type 1 Diabetes, Alopecia Areata, and long COVID in our current clinical trials. Additional autoimmune diseases that have been tested with Educator Therapy include: Type 2 Diabetes, Lupus, Psoriasis, Graves’ Disease, Hashimoto’s Disease, Scleroderma, Eczema, Sjogren’s Syndrome, Parkinson’s Disease, and Amyotrophic Lateral Sclerosis (ALS). Further research is being developed to use Educator Therapy to treat additional incurable diseases.
Stem Cell Educator Therapy (i.e. Educator Therapy) is an in vitro process where a patient’s white blood cells are collected and educated inside a Stem Cell Educator device that is coated with cord blood stem cells, CB-SC. The patient’s white blood cells (immune cells) intercept the CB-SC’s communications, re-educating the cells back to their pre-diseased state. This process then circulates the ‘educated’ white blood cells (GleukocellTM) back into the patient through the infusion. The newly ‘educated’ cells then educate other defective cells in the patient’s body on who to fight and who to protect. This immune reset allows the patient’s immune system to fight for its healing the way it was initially designed.
Educator Therapy does not introduce stem cells or reagents into patients, ensuring 100% immune acceptance and zero risk of rejection.
Dr. Yong Zhao discovered and patented the human umbilical-cord blood stem cell (CB-SC) in 2005. He later found that CB-SC are also found in human adult blood, known as peripheral blood insulin-producing stem cells (PB-IPC, or PB-SC). CB-SC are more powerful than any other multipotent stem cells. They completely eliminate the requirement for stem cell matching because they have very low immunogenicity. Stem Cell Educator Therapy is the only technology in the world licensed to use these stem cells.
Depending on the facility, the Stem Cell Educator Therapy may be administered in one of two ways: closed-looped treatment or open-looped treatment. Both treatments provide a patient with their own blood separator and Educator device.
For closed-looped treatment, the patient’s blood is cycled from one arm to a blood separator (apheresis machine) where their white bloods are separated (the red blood cells are immediately returned to the body). Next, their white blood cells are passed through the Stem Cell Educator device where they are treated (re-educated) and then directly returned to the patient’s body through the other arm. This continuous loop lasts for 8 to 9 hours.
For open-looped treatment, the process is split between two days. On day one, the patient’s blood is drawn and about 250 milliliters of white blood cells are separated over the course of 4-5 hours (the red blood cells are immediately returned to the body). Overnight, the white blood cells are incubated in the Stem Cell Educator device for 17 hours. On day two, the patient returns to the facility and the treated white blood cells (GleukocellTM) are infused back into their body.
No stem cell injections, transplantations, or blood transfusions occur in Educator Therapy. Instead, Educator Therapy utilizes an in vitro method where CB-SC are contained in the patient’s personal Educator Device. This ensures immune acceptance and eliminates any risks of rejection, as the cells entering the patient’s body are their own white blood cells that have been treated by the CB-SC.
Yes, zero stem cells from animals or aborted fetuses are used in Educator Therapy, as these treatment methods result in safety risks, ethical and religious concerns.
No, Educator Therapy does not require genetic matching. CB-SC, the multipotent stem cells used in Educator Therapy, have very low immunogenicity and therefore eliminate the requirement for genetic stem cell matching.
Throne Biotechnologies partners with domestic (umbilical) cord blood banks. All cord blood provided to Throne Biotechnologies Inc. for Educator Therapy is thoroughly screened.
No, Educator Therapy does not use any stored cord blood. The freezing process that occurs when cord blood is stored results in a 20% loss of stem cells. For this reason, Educator Therapy only uses fresh umbilical cord blood obtained from domestic cord blood banks. There is no benefit to using personal stored cord blood because CB-SC eliminate the need for genetic matching in Educator Therapy’s in vitro process.
Our clinical trials provide powerful evidence that a single treatment with Educator Therapy may provide lasting reversal of autoimmunity. Type 1 and Type 2 Diabetes patients have experienced both significant reduction and complete elimination of insulin injections. Alopecia patients have achieved full restoration of scalp hairs, eyebrows, eyelashes, and body hairs. These are just a few examples of the benefits of Educator Therapy.
Autoimmunity is complex because every individual’s body responds differently. Patients must recognize their role in maintaining a healthy lifestyle post-treatment to foster their renewed autoimmunity.
Educator Therapy can provide lasting reversal autoimmunity through one treatment. Most patients receive one treatment. Some severe cases may require additional treatment 6-12 months later. We will examine patient’s immune markers by flow cytometry during the follow-ups, and determine whether and when need for the additional treatment.
One treatment of Educator Therapy will take roughly 9 to 10 hours, often split between two days.
After treatment, patients are encouraged to monitor their normative response (i.e. clinical outcomes) through their family doctors and/or endocrinologist. Follow-up testing will be performed at their local labs (e.g., LabCorp or Quest), and send their blood samples to Throne for flow cytometry analysis. As they monitor their normative responses post-treatment, they can adjust any typical dosages based on their family doctor’s recommendations.
Dr. Zhao has successfully published multiple peer-reviewed clinical journals detailing the safety and effectiveness of Stem Cell Educator Therapy. Click the link below to read Throne’s Journal Publications.
Clinical trials have proven Educator Therapy to be safe, non-invasive and effective with one treatment producing lasting improvement in metabolic control and immune modulation.
Throne Biotechnologies has received the U.S. FDA approvals for Regenerative Medicine Advanced Therapy (RMAT) designation by using Stem Cell Educator therapy to treat recent onset type 1 diabetic patients (IND 19247), and IND 19246 for alopecia aerate, and IND 19679 for COVID-19. It is anticipated to conclude within the next two years, at which point Educator Therapy will be FDA approved for commercialization. Please click the link below to be redirected to the FDA’s website where you can read further about the development and approval process.
Yes, Educator Therapy is safe and non-invasive. Unlike any other stem cell treatment, Educator Therapy does not introduce stem cells or reagents into patients, ensuring 100% immune acceptance and no risk of rejection.
As Educator Therapy is a minimum-invasive treatment through apheresis (white blood cell collection) and infusion with two i.v. canulations, there are no major risks or safety concerns associated with it.
Individuals who undergo Educator Therapy experience minimal to zero side effects. Minimal side effects include slight discomfort and tingling/numbness of fingers/lips from the apheresis process (blood draw and white blood cell collection).
